Lifecare ASA: Share capital increase and warrants registered

Reference is made to the stock exchange announcement published by Lifecare ASA (the "Company") on 22 January 2026 regarding the final results of the partially underwritten rights issue of new shares in the Company (the "Rights Issue").

The share capital increase pertaining to the issuance of 160,000,000 new shares in the Rights Issue has now been registered with the Norwegian Register of Business Enterprises. The Company's new share capital is NOK 17,906,097.30 divided on 179,060,973 shares, each with a par value of NOK 0.10.

Subscribers in the Rights Issue were allocated warrants in two series: (a) three (3) warrants for every four (4) new shares allocated to, and paid by, them in the Rights Issue, which will be exercisable in the exercise period from 2 March 2026 to 13 March 2026 ("Warrants Series 1"); and (b) three (3) warrants for every four (4) new shares allocated to, and paid by, them in the Rights Issue, which will be exercisable in the exercise period from 1 June 2026 to 12 June 2026 ("Warrants Series 2" and together with Warrants Series 1, the "Warrants"). The issuance of the in total 240,000,066 Warrants allocated to subscribers in the Rights Issue (divided on 120,000,033 Warrants Series 1 and 120,000,033 Warrants Series 2) has now been registered with the Norwegian Register of Business Enterprises.

About us Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities Trading Act, §5-12. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-01-28 17:29 CET.